Lethal midline granuloma
Drug research and approvals for lethal midline granuloma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 23 studies of lethal midline granuloma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 23
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 23 recruiting on ClinicalTrials.gov ↗
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative DiseasesNCT07727083 · Not reported · Rong Tao · starts Aug 11, 2026
- BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCLNCT07678229 · Phase 3 · Rong Tao · starts Aug 11, 2026
- A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma…NCT07628738 · Phase 2 · Ruijin Hospital · starts Jul 1, 2026
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the…NCT07525466 · Phase 1 / Phase 2 · Beijing Tongren Hospital · starts Apr 1, 2026
- Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaNCT07502768 · Phase 1 / Phase 2 · Rong Tao · starts Apr 30, 2026
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLNCT07380984 · Phase 2 · Ruijin Hospital · starts Mar 1, 2026
- Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaNCT07162012 · Early Phase 1 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · starts Sep 20, 2025
- A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage…NCT07000617 · Phase 2 · Peking University Cancer Hospital & Institute · starts Mar 21, 2025
- Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaNCT06824883 · Phase 2 · Peking Union Medical College Hospital · starts May 20, 2024
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications
Phase 3 10
- PegaspargaseAsparagine hydrolytic enzyme
- DexamethasoneGlucocorticoid receptor agonist
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- OxaliplatinDNA inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- CyclophosphamideDNA inhibitor
- SugemalimabProgrammed cell death 1 ligand 1 binding agent
Phase 2 12 of 15
- SintilimabProgrammed cell death protein 1 antagonist
- MitoxantroneDNA topoisomerase II alpha inhibitor
- CisplatinDNA inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- BasiliximabInterleukin-2 receptor inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
- ToripalimabProgrammed cell death protein 1 antagonist
Phase 1 or earlier 3
- IrinotecanDNA topoisomerase I inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- UCN-01Cyclin-dependent kinase 2 inhibitor
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA